Dyne Therapeutics, Inc. $DYN Stock Acquired by CenterBook Partners LP

CenterBook Partners LP lifted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 167.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,650 shares of the company’s stock after buying an additional 36,112 shares during the quarter. CenterBook Partners LP’s holdings in Dyne Therapeutics were worth $929,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. BlackRock Inc. acquired a new position in Dyne Therapeutics during the second quarter worth $275,500,000. Jupiter Topco LLC purchased a new position in Dyne Therapeutics in the second quarter worth $266,634,000. Perceptive Advisors LLC lifted its holdings in Dyne Therapeutics by 34.2% in the first quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock valued at $84,646,000 after acquiring an additional 1,189,895 shares during the period. Orbimed Advisors LLC lifted its holdings in Dyne Therapeutics by 32.5% in the first quarter. Orbimed Advisors LLC now owns 2,917,884 shares of the company’s stock valued at $52,901,000 after acquiring an additional 715,700 shares during the period. Finally, Bank of America Corp DE acquired a new stake in Dyne Therapeutics in the second quarter valued at $49,604,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Dyne Therapeutics

In other news, Director Brian Posner purchased 2,500 shares of the company’s stock in a transaction dated Friday, October 2nd. The stock was acquired at an average price of $16.00 per share, for a total transaction of $40,000.00. Following the completion of the transaction, the director directly owned 27,000 shares in the company, valued at $432,000. This represents a 10.20% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Jason Rhodes sold 2,160,516 shares of Dyne Therapeutics stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the transaction, the director directly owned 428,946 shares of the company’s stock, valued at $10,723,650. This trade represents a 83.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 2,598,706 shares of company stock worth $65,432,671. Corporate insiders own 9.46% of the company’s stock.

Analyst Ratings Changes

DYN has been the topic of several research analyst reports. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from a “neutral” rating to an “underweight” rating and decreased their target price for the stock from $17.00 to $10.00 in a research report on Wednesday, September 9th. HC Wainwright cut their price target on shares of Dyne Therapeutics from $50.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Oppenheimer cut shares of Dyne Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $40.00 to $15.00 in a research note on Wednesday, October 28th. Royal Bank Of Canada decreased their price objective on shares of Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.29.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $17.92 on Wednesday. Dyne Therapeutics, Inc. has a 1-year low of $14.00 and a 1-year high of $27.31. The company has a market capitalization of $3.36 billion, a P/E ratio of -4.94 and a beta of 1.22. The business has a 50 day moving average price of $17.42 and a 200 day moving average price of $19.34. The company has a debt-to-equity ratio of 0.21, a current ratio of 12.99 and a quick ratio of 12.99.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.15). During the same period in the previous year, the business earned ($0.76) earnings per share. Sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.77 EPS for the current fiscal year.

Key Stories Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $32 price target. It also raised its Q4 2026 EPS estimate to a loss of $0.95 per share from $1.01, a modest improvement. Dyne Therapeutics analyst estimates
• Neutral Sentiment: A short-interest update reported zero shares sold short and a 0.0-day short-interest ratio, despite describing short interest as having increased significantly. The figures are contradictory, so they offer little reliable indication of investor positioning.
• Negative Sentiment: HC Wainwright lowered its projected EPS for FY2027, FY2028 and FY2029, implying larger expected losses in those years. Its FY2026 estimate also edged lower; the company is expected to remain loss-making. Dyne Therapeutics analyst estimates

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.